JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Description

This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

Conditions

Advanced Solid Tumor, NSCLC, CRC

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Condition
Advanced Solid Tumor
Intervention / Treatment

-

Contacts and Locations

Phoenix

Mayo Clinc, Phoenix, Arizona, United States, 85054

Scottsdale

Mayo Clinc, Scottsdale, Arizona, United States, 85259

Jacksonville

Mayo Clinc, Jacksonville, Florida, United States, 32224

Salt Lake City

University of Utah, Salt Lake City, Utah, United States, 84112

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants must be able to provide an archived tumor sample
  • * Histologically or cytologically confirmed solid tumors with KRAS G12C mutation
  • * Must have received at least 1 prior standard therapy
  • * Must have at least 1 measurable lesion per RECIST v1.1
  • * Must have adequate organ function
  • * Must be able to swallow and retain orally administered medication
  • * Has brain or spinal metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days
  • * Active infection requiring systemic treatment within 7 days
  • * Active HBV or HCV
  • * Any severe and/or uncontrolled medical conditions
  • * LVEF ≤50% assessed by ECHO or QTcF
  • * QT interval \>470 msec
  • * Experiencing unresolved CTCAE 5.0 Grade \>1 toxicities

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jacobio Pharmaceuticals Co., Ltd.,

Study Record Dates

2025-07